Physician profile
David Moore
NPI 1497198261
$8,627.73
in general payments reported to CMS, 2019-2025
45 companies · $842 in 2025
The $842 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $750 · 2021: $982 · 2022: $645 · 2023: $2,849 · 2024: $2,020 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,913 · Travel and Lodging: $2,798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,913.20 |
| Travel and Lodging | $2,797.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,332.46 | 2019-2025 | Ams 700 |
| Astellas Pharma US INC | $580.68 | 2019-2024 | Xtandi, Myrbetriq |
| Pfizer INC. | $490.57 | 2019-2025 | |
| Janssen Biotech, INC. | $480.49 | 2019-2025 | Erleada |
| 180 Medical, INC. | $283.84 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $270.74 | 2020-2025 | Keytruda, Welireg, Lynparza |
| Abbvie INC. | $243.93 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $237.21 | 2023-2025 | Gemtesa, Orgovyx |
| Endo Pharmaceuticals INC. | $176.64 | 2019-2023 | Aveed, Xiaflex |
| Histosonics, INC. | $160.00 | 2025 | |
| Medtronic USA, INC. | $158.78 | 2019-2020 | |
| Medtronic, INC. | $156.05 | 2021-2024 | Interstim |
| Allergan, INC. | $137.34 | 2019-2021 | |
| Tolmar Pharmaceuticals, INC. | $132.31 | 2020-2022 | |
| Myriad Genetic Laboratories, INC. | $131.82 | 2021-2024 | Prolaris |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.